Skip to content
Peptidepedia

Semax Results: Timeline, Before & After & What to Expect (2026)

From Peptidepedia, the trusted peptide wiki.

Results Timelines

Minutes to Hours:

  • Increased subjective alertness and mental clarity (commonly reported within 15 to 30 minutes of intranasal dosing)
  • Enhanced focus and verbal fluency
  • Mild mood elevation and motivation

Days to Weeks (1 to 2 Weeks):

  • More consistent improvements in working memory and attention span
  • Reduced mental fatigue under sustained cognitive load
  • Improved sleep quality (when dosed appropriately in the morning)

Weeks 2 to 4+:

  • Cumulative neurotrophic effects, BDNF-driven synaptic remodeling and neuroplasticity
  • Enhanced learning capacity and information retention
  • In stroke patients: progressive restoration of motor and neurological function
  • In optic nerve disease: measurable improvements in visual field and electrophysiological parameters
The rapid onset of acute effects reflects direct neurotransmitter modulation, while longer-term benefits correspond to BDNF-mediated structural changes in neural circuitry that require sustained neurotrophin signaling.

Frequently Asked Questions

N-Acetyl Semax Amidate (NASA) is a modified version of Semax with acetylation at the N-terminus and amidation at the C-terminus. These modifications shield both ends of the peptide from enzymatic degradation, resulting in enhanced stability, improved blood-brain barrier penetration, and a longer duration of action compared to standard Semax. Dosing is typically 30 to 40% lower than standard Semax due to increased bioavailability.

This content is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making any health-related decisions.

References

  1. Dergunova LV, Filippenkov IB, Stavchansky VV, et al. Novel insights into the protective properties of ACTH(4-7)PGP (Semax) peptide at the transcriptome level following cerebral ischaemia-reperfusion in rats. Genes (Basel). 2020;11(6):681.
  2. Filippenkov IB, Stavchansky VV, Denisova AE, et al. Novel insights into the protective properties of ACTH(4-7)PGP (Semax) peptide at the transcriptome level following cerebral ischaemia-reperfusion in rats. BMC Neurosci. 2014;15:63.
  3. Shadrina MI, Dolotov OV, Grivennikov IA, et al. Comparison of the temporary dynamics of NGF and BDNF gene expression in rat hippocampus, frontal cortex, and retina under Semax action. J Mol Neurosci. 2010;41(1):30-35.
  4. Eremin KO, Kudrin VS, Saransaari P, Oja SS, Grivennikov IA, Myasoedov NF, Rayevsky KS. Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochem Res. 2005;30(12):1493-1500.
  5. Kaplan AY, Kochetova AG, Nezavibathko VN, Rzhevskii DA, Roshchina IF, Ashmarin IP. Semax, an analogue of adrenocorticotropin (4-10), is a potential agent for the treatment of attention-deficit hyperactivity disorder and Rett syndrome. Med Hypotheses. 2007;68(2):306-310.
  6. Gusev EI, Skvortsova VI, Chukanova EI. The efficacy of semax in the treatment of patients at different stages of ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova. 2018;118(3):61-68.
  7. Gavrilova SA, Golubev AI, Lipina TV, et al. Investigation of mechanisms of neuro-protective effect of semax in acute period of ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova. 1999;99(5):15-19.
  8. Ioseliani TK, Kozaev GG, Poletaeva II, Elizarova IP. Semax in the treatment of glaucomatous optic neuropathy in patients with normalized ophthalmic tone. Vestn Oftalmol. 2001;117(4):5-8.
  9. Filippenkov IB, Remizova JA, Denisova AE, et al. Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia. Cell Mol Neurobiol. 2024;44(1):71.
  10. Myasoedov NF, Andreyeva LA, Grigorjeva ME, et al. Development of peptide biopharmaceuticals in Russia. Pharmaceutics. 2022;14(4):716.
  11. Stavchansky VV, Dergunova LV, Filippenkov IB, et al. Brain protein expression profile confirms the protective effect of the ACTH(4-7)PGP peptide (Semax) in a rat model of cerebral ischemia-reperfusion. Int J Mol Sci. 2021;22(12):6179.
←Read the full Semax guide

“Peptidepedia compiles and maintains peptide information from peer-reviewed research, clinical trials, and verified laboratory data.”